Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Traws Pharma ( (TRAW) ) has provided an update.
On October 12, 2025, Traws Pharma‘s Compensation Committee approved stock options for its executive officers, with a total of 184,492 options granted. The options, priced at $3.01 per share, will vest in one year, enhancing executive retention and aligning management interests with shareholder value.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is known for its work in virology and other medical fields, aiming to address unmet medical needs.
Average Trading Volume: 158,531
Technical Sentiment Signal: Sell
Current Market Cap: $19.03M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.